Zepp Health - ADR - Class A opened higher at $2.46, compared with its previous close of $2.38. In the last trading session, the stock traded between $2.39 and $2.72. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Zepp Health - ADR - Class A is now worth
$ 6.92
Resulting in a loss of
$ 93.08 (93.08%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.13 (+5.42%)
Day High
$2.72
Day Low
$2.39
Day Open
$2.46
Prev Close
$2.38
Volume
61,892
1W Return
11.02%
1M Return
-30.31%
3M Return
-51.47%
6M Return
-77.78%
1Y Return
-90.44%
Fundamentals
Market Cap ($ Mn)
21
PE Ratio
-
PB Ratio
0.38
PEG Ratio
-
ROE
-17.42%
ROCE
-10.30%
EPS (TTM)
-
Investment Returns
1 Week
11.02%
1 Month
-30.31%
3 Months
-51.47%
6 Months
-77.78%
9 Months
-89.54%
Financials
Quarterly
All values in $ Mn
38.5
Mar 25
59.4
Jun 25
75.8
Sep 25
85.2
Dec 25
51.5
Mar 26
63.5
Jun 26
Updates
10Nov
Zepp Health to report Q3FY26 results on November 22
Zepp Health Corporation will report Q3FY26 results on November 22, 2026. Conference call scheduled for 8:30 pm ET on the same day. Company has shipped over 200 million smart wearable devices globally. Live webcast available via investor relations website.
2 days ago
1Sep
Zepp Health Q1FY26 Results: Revenue up 33.8% to $51.5 million
Revenue grew 33.8% YoY to $51.5 million, driven by new product launches like T-Rex Ultra 2. Gross margin expanded to 37.7%, aided by a 20% rise in average selling prices. Operating loss narrowed to $6.3 million from $17.2 million in the prior year period. Company secured a three-year exclusive global partnership with hybrid training brand HYROX. Q2 2026 revenue guidance set at $63-68 million, implying 6-14% YoY growth.
2mo ago
9Jun
Zepp Health sales rise 33.8% in Q1, led by new product launches
Zepp Health Corporation reported unaudited financial results for the first quarter of 2026, with revenue rising 33.76% year-over-year to US$51.547 million. The company's adjusted net loss narrowed to US$17.9 million, while gross margin expanded to 37.7%. For the second quarter of 2026, management expects net revenues between US$63.0 million and US$68.0 million.
